These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33049748)

  • 41. Testicular germ cell tumour cells release microRNA-containing extracellular vesicles that induce phenotypic and genotypic changes in cells of the tumour microenvironment.
    Alonso-Crisostomo L; Trendell J; Ferraresso M; Bailey S; Ward D; Scurlock ZGL; Wenlock SC; Bastos CAP; Jugdaohsingh R; Faria NJ; Enright AJ; Scarpini CG; Coleman N; Murray MJ
    Int J Cancer; 2024 Jan; 154(2):372-388. PubMed ID: 37632231
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
    Herr HW; Toner GC; Geller NL; Bosl GJ
    Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical utility of circulating miR-371a-3p for the management of patients with intracranial malignant germ cell tumors.
    Murray MJ; Ajithkumar T; Harris F; Williams RM; Jalloh I; Cross J; Ronghe M; Ward D; Scarpini CG; Nicholson JC; Coleman N
    Neurooncol Adv; 2020; 2(1):vdaa048. PubMed ID: 32642701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours.
    Dieckmann KP; Grobelny F; Soave A; Che Y; Nestler T; Matthies C; Heinzelbecker J; Winter A; Heidenreich A; Niemzok T; Dumlupinar C; Angerer M; Wülfing C; Paffenholz P; Belge G
    Eur Urol Focus; 2024 May; ():. PubMed ID: 38729824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours.
    Dieckmann KP; Spiekermann M; Balks T; Flor I; Löning T; Bullerdiek J; Belge G
    Br J Cancer; 2012 Nov; 107(10):1754-60. PubMed ID: 23059743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.
    Ye F; Feldman DR; Valentino A; So R; Bromberg M; Khan S; Funt SA; Sheinfeld J; Solit DB; Pessin MS; Peerschke EI
    J Mol Diagn; 2022 Aug; 24(8):867-877. PubMed ID: 35934321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
    Nguyen CT; Stephenson AJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation.
    Boellaard WPA; Gillis AJM; van Leenders GJLH; Stoop H; van Agthoven T; Dorssers LCJ; Dinkelman-Smit M; Boormans JL; Looijenga LHJ
    Andrology; 2019 Jul; 7(4):463-468. PubMed ID: 30786164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection.
    Lafin JT; Kenigsberg AP; Meng X; Abe D; Savelyeva A; Singla N; Woldu SL; Lotan Y; Mauck RJ; Lewis CM; Margulis V; Wong D; Jia L; Kapur P; Xu L; Speir RW; Chesnut GT; Frazier AL; Strand DW; Coleman N; Murray MJ; Amatruda JF; Bagrodia A
    Eur Urol Open Sci; 2021 Apr; 26():83-87. PubMed ID: 33997822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours.
    Bagrodia A; Savelyeva A; Lafin JT; Speir RW; Chesnut GT; Frazier AL; Woldu SL; Margulis V; Murray MJ; Amatruda JF; Lotan Y
    BJU Int; 2021 Jul; 128(1):57-64. PubMed ID: 33124175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical impact of MDR1-expression in testicular germ cell cancer.
    Schrader AJ; Seger M; Konrad L; Olbert P; Hegele A; Hofmann R; Heidenreich A
    Exp Oncol; 2007 Sep; 29(3):212-6. PubMed ID: 18004247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic markers for germ cell neoplasms: from placental-like alkaline phosphatase to micro-RNAs.
    Rajpert-De Meyts E; Nielsen JE; Skakkebaek NE; Almstrup K
    Folia Histochem Cytobiol; 2015; 53(3):177-88. PubMed ID: 26306513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.
    Nestler T; Kremer L; von Brandenstein M; Wittersheim M; Paffenholz P; Wagener-Ryczek S; Quaas A; Hellmich M; Müller S; Pfister D; Odenthal M; Heidenreich A
    Cancer; 2023 Feb; 129(4):634-642. PubMed ID: 36504384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The metastatic potential of seminomatous germ cell tumours is associated with a specific microRNA pattern.
    Ernst S; Heinzelmann J; Bohle RM; Weber G; Stöckle M; Junker K; Heinzelbecker J
    Andrology; 2020 Nov; 8(6):1687-1698. PubMed ID: 32530514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-treatment Residual Clinicopathological Outcomes in Testicular Germ Cell Tumours.
    Nagaraj RV; Rao BV; Yoganarsimha J; Fonseca D; Kodandapani S; Giridhar A; Sharma R; Rajappa S; Rao TS; Sundaram C
    Indian J Surg Oncol; 2022 Sep; 13(3):505-510. PubMed ID: 36187518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of viable germ cell tumor in postchemotherapeutic residual retroperitoneal masses.
    Al Othman K; Al Hathal N; Mokhtar A
    Urol Ann; 2014 Jan; 6(1):27-30. PubMed ID: 24669118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
    Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.